You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
騰盛博藥-B(02137.HK)與VBI(VBIV.US)戰略合作 拓展乙型肝炎領域
騰盛博藥-B(02137.HK)公布,與VBI(VBIV.US)簽訂許可協議,以拓展雙方在乙型肝炎(HBV)領域的戰略合作。 公司將從VBI獲得BRII-179(VBI-2601)的全球獨家開發和商業化權利,將BRII-179(VBI-2601)獨家許可從大中華區擴大至全球市場。此外,公司還將從VBI獲得PreHevbri在大中華區及包括澳洲、印尼、馬來西亞、新西蘭、菲律賓、新加坡、南韓、泰國和越南等若干亞太國家的開發和商業化權利。 根據協議條款,VBI將有權獲得BRII-179(VBI-2601)和PreHevbri 700萬美元的首付款許可費,並有資格獲得未來開發和商業化的潛在里程碑付款以及基於未來年淨銷售額的特許權使用費。 公司另與VBI訂立供應協議,VBI將製造及向公司供應BRII-179(VBI-2601)或PreHevbri,而公司將向VBI支付500萬美元的預付款。此外,在若干交割條件的規限下,公司將對VBI作出300萬美元的 股權投資。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account